文献速递心境障碍

KCNQ通道开放剂依佐加滨对重性抑郁障碍患者腹侧纹状体功能连接及临床症状的影响

Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
PubMed 文献 · Mol Psychiatry · 2018-11-01

治疗后抑郁症状(MADRS评分变化-13.7±9.7,p<0.001,d=2.08)及快感缺失症状(SHAPS评分变化-6.1±5.3,p<0.001,d=1.00)显著减轻,且抑郁改善与腹侧尾状核与中扣带回及后扣带回功能连接降低相关(n=14,体素水平p<0.005),部分患者(n=9)奖励学习改善。

要点

  • 依佐加滨治疗10周显著降低MDD患者抑郁及快感缺失症状。
  • 抑郁改善伴随腹侧尾状核与扣带回功能连接降低。
  • 部分患者奖励学习改善,提示KCNQ通道为潜在靶点。

核心结论

  • KCNQ通道开放剂依佐加滨可能通过调节腹侧纹状体 reward 环路改善MDD抑郁及快感缺失症状。

研究设计与样本

  • 基线及治疗后采集静息态功能磁共振数据,部分患者(n=9)进行概率奖励任务测试。

主要发现

  • 治疗后MADRS评分变化为-13.7±9.7(p<0.001,d=2.08),SHAPS评分变化为-6.1±5.3(p<0.001,d=1.00)。
  • 控制整体抑郁严重度后,快感缺失改善仍显著。
  • 抑郁改善与腹侧尾状核与中扣带回及后扣带回功能连接降低相关(n=14,体素水平p<0.005)。
  • 概率奖励任务亚组(n=9)显示治疗后奖励学习增加。

临床怎么用

  • 目前证据仅来自小样本开放标签研究,尚不能支持临床常规使用依佐加滨治疗MDD。
  • KCNQ通道可作为未来心境障碍药物研发的潜在靶点,需进一步随机对照试验验证。

局限性

  • 奖励任务仅亚组(n=9)完成,功能连接分析样本为n=14,统计效力有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment strategies remain limited in their mechanistic diversity. Recent evidence has highlighted a promising novel pharmaceutical target-the KCNQ-type potassium channel-for the treatment of depressive disorders, which may exert a therapeutic effect via functional changes within the brain reward system, including the ventral striatum. The current study assessed the effects of the KCNQ channel opener ezogabine (also known as retigabine) on reward circuitry and clinical symptoms in patients with MDD. Eighteen medication-free individuals with MDD currently in a major depressive episode were enrolled in an open-label study and received ezogabine up to 900 mg/day orally over the course of 10 weeks. Resting-state functional magnetic resonance imaging data were collected at baseline and posttreatment to examine brain reward circuitry. Reward learning was measured using a computerized probabilistic reward task. After treatment with ezogabine, subjects exhibited a significant reduction of depressive symptoms (Montgomery-Asberg Depression Rating Scale score change: -13.7 ± 9.7, p < 0.001, d = 2.08) and anhedonic symptoms (Snaith-Hamilton Pleasure Scale score change: -6.1 ± 5.3, p < 0.001, d = 1.00), which remained significant even after controlling for overall depression severity. Improvement in depression was associated with decreased functional connectivity between the ventral caudate and clusters within the mid-cingulate cortex and posterior cingulate cortex (n = 14, voxel-wise p < 0.005). In addition, a subgroup of patients tested with a probabilistic reward task (n = 9) showed increased reward learning following treatment. These findings highlight the KCNQ-type potassium channel as a promising target for future drug discovery efforts in mood disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tan A, Costi S, Morris LS, et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol Psychiatry. 2018. PMID: 30385872. doi:10.1038/s41380-018-0283-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。